Behçet’s disease is a rare chronic inflammatory condition affecting multiple organs, causing debilitating symptoms such as oral ulcers, joint pain, and uveitis. A groundbreaking Italian study, led by Professor Giuseppe Lopalco from the University of Bari and supported by the Italian Foundation for Rheumatology Research (FIRA), provides new insights into optimizing treatments through a personalized approach.
The study, conducted across seven centers in Italy and Spain, evaluated the effectiveness of two biologic therapies: TNF inhibitors and apremilast, commonly used for psoriasis and psoriatic arthritis. Findings underscore the importance of tailoring therapies to individual patient needs.
Personalized care: key findings from the study
With 78 participants, researchers revealed that:
- TNF inhibitors: Best suited for severe cases with systemic involvement, such as uveitis and vascular complications.
- Apremilast: Ideal for milder forms, helping reduce corticosteroid dependency but associated with higher discontinuation rates due to gastrointestinal side effects.
“Thanks to these findings, clinicians can now offer more targeted treatments, enhancing efficacy and minimizing side effects,” states Professor Lopalco. Additionally, the study highlights the potential role of JAK inhibitors, already used in rheumatoid arthritis, as a promising therapeutic avenue for Behçet’s disease.
FIRA’s role in advancing research
The Italian Foundation for Rheumatology Research drives innovative and independent projects to improve the management of rheumatic diseases, which affect over 5 million people in Italy. Through funding and collaboration, FIRA is instrumental in advancing scientific progress and providing better solutions for patients.
FIRA President Carlomaurizio Montecucco emphasizes how research has revolutionized rheumatology care, allowing patients to achieve an improved quality of life that was unimaginable decades ago.
